{"pre_text": ["part iii item 10 .", "directors and executive officers of the registrant .", "pursuant to section 406 of the sarbanes-oxley act of 2002 , we have adopted a code of ethics for senior financial officers that applies to our principal executive officer and principal financial officer , principal accounting officer and controller , and other persons performing similar functions .", "our code of ethics for senior financial officers is publicly available on our website at www.hologic.com.we intend to satisfy the disclosure requirement under item 5.05 of current report on form 8-k regarding an amendment to , or waiver from , a provision of this code by posting such information on our website , at the address specified above .", "the additional information required by this item is incorporated by reference to our definitive proxy statement for our annual meeting of stockholders to be filed with the securities and exchange commission within 120 days after the close of our fiscal year .", "item 11 .", "executive compensation .", "the information required by this item is incorporated by reference to our definitive proxy statement for our annual meeting of stockholders to be filed with the securities and exchange commission within 120 days after the close of our fiscal year .", "item 12 .", "security ownership of certain beneficial owners and management and related stockholder matters .", "we maintain a number of equity compensation plans for employees , officers , directors and others whose efforts contribute to our success .", "the table below sets forth certain information as our fiscal year ended september 25 , 2004 regarding the shares of our common stock available for grant or granted under stock option plans that ( i ) were approved by our stockholders , and ( ii ) were not approved by our stockholders .", "equity compensation plan information plan category number of securities to be issued upon exercise of outstanding options , warrants and rights weighted-average exercise price of outstanding options , warrants and rights number of securities remaining available for future issuance under equity compensation plans ( excluding securities reflected in column ( a ) ) equity compensation plans approved by security holders ( 1 ) .", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", "2560530 $ 11.71 523390 equity compensation plans not approved by security holders ( 2 ) .", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", ".", "865212 $ 9.06 321436 ."], "post_text": ["( 1 ) includes the following plans : 1986 combination stock option plan ; amended and restated 1990 non-employee director stock option plan ; 1995 combination stock option plan ; amended and restated 1999 equity incentive plan ; and 2000 employee stock purchase plan .", "also includes the following plans which we assumed in connection with our acquisition of fluoroscan imaging systems in 1996 : fluoroscan imaging systems , inc .", "1994 amended and restated stock incentive plan and fluoroscan imaging systems , inc .", "1995 stock incentive plan .", "for a description of these plans , please refer to footnote 5 contained in our consolidated financial statements. ."], "table": [["plan category", "number of securities to be issued upon exerciseof outstanding options warrants and rights ( a )", "weighted-average exercise price of outstanding options warrants and rights ( b )", "number of securities remaining available for future issuance under equitycompensation plans ( excluding securities reflected in column ( a ) ) ( c )"], ["equity compensation plans approved by security holders ( 1 )", "2560530", "$ 11.71", "523390"], ["equity compensation plans not approved by security holders ( 2 )", "865212", "$ 9.06", "321436"], ["total", "3425742", "$ 11.04", "844826"]], "table_ori": [["Plan Category", "Number Of Securities To Be Issued Upon ExerciseOf Outstanding Options, Warrants And Rights (a)", "Weighted-Average Exercise Price Of Outstanding Options, Warrants And Rights (b)", "Number Of Securities Remaining Available For Future Issuance Under EquityCompensation Plans (excluding securities reflected in column (a)) (c)"], ["Equity compensation plans approved by security holders (1)", "2,560,530", "$11.71", "523,390"], ["Equity compensation plans not approved by security holders (2)", "865,212", "$9.06", "321,436"], ["Total", "3,425,742", "$11.04", "844,826"]]}

Question: what would the total cash impact be if all outstanding options warrants and rights were exercised?
Evidence:
table_3: plan category the total of number of securities to be issued upon exerciseof outstanding options warrants and rights ( a ) is 3425742 ; the total of weighted-average exercise price of outstanding options warrants and rights ( b ) is $ 11.04 ; the total of number of securities remaining available for future issuance under equitycompensation plans ( excluding securities reflected in column ( a ) ) ( c ) is 844826 ;
Program: multiply(11.04, 3425742)
Answer:
str_answer: 37820191.68
exe_answer: 37820191.68